Liu C, Yin F, Zhang Z
Department of Endocrinology, First Affiliated Hospital, Nanjing Medical University.
Zhonghua Nei Ke Za Zhi. 1995 Feb;34(2):105-7.
Thyroid stimulating antibodies (TSAb) and TSH binding inhibitor immunoglobulins (TBII) were assessed in patients with thyroid diseases. The activity of TSAb and TBII was significantly higher in patients with untreated Graves' disease (GD) as compared with that in patients with remitted GD and Hashimoto's thyroiditis, while the latter two groups had higher TSAb and TBII activity than patients with thyroid adenoma or control subjects. Of 24 patients with untreated GD, TSAb and TBII were detected in 22 and 19 respectively. The positive rates of TSAb and TBII in patients with remitted GD or Hashimoto's thyroiditis were 0.48 and 0.44 or 0.231 and 0.615. Both TSAb and TBII were negative in patients with thyroid adenoma or controls. No statistical correlation was found between TSAb and TBII activity, suggesting the coexistence of heterogeneous populations of TSH receptor antibodies.
对甲状腺疾病患者进行了促甲状腺素抗体（TSAb）和促甲状腺素结合抑制性免疫球蛋白（TBII）检测。与缓解期Graves病（GD）患者和桥本甲状腺炎患者相比，未经治疗的GD患者中TSAb和TBII的活性显著更高，而后两组患者的TSAb和TBII活性高于甲状腺腺瘤患者或对照者。在24例未经治疗的GD患者中，分别有22例检测到TSAb，19例检测到TBII。缓解期GD患者或桥本甲状腺炎患者中TSAb和TBII的阳性率分别为0.48和0.44或0.231和0.615。甲状腺腺瘤患者或对照者中TSAb和TBII均为阴性。未发现TSAb和TBII活性之间存在统计学相关性，提示促甲状腺素受体抗体存在异质性群体共存。
